{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:42:10Z","timestamp":1784191330779,"version":"3.55.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.<\/jats:p>","DOI":"10.1097\/inf.0000000000002045","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T21:33:57Z","timestamp":1522359237000},"page":"e26-e28","source":"Crossref","is-referenced-by-count":2,"title":["Safety, Effectiveness and Exposure-response of Micafungin in Infants"],"prefix":"10.1097","volume":"38","author":[{"given":"Nazario D.","family":"Rivera-Chaparro","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ericson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Wu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brian","family":"Smith","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese H.","family":"Clark","sequence":"additional","affiliation":[{"name":"Pediatrix Medical Group, Inc., Sunrise, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel G.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12879-014-0725-7","article-title":"Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.","volume":"14","author":"Viscoli","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.2004-2292","article-title":"Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.","volume":"117","author":"Benjamin","year":"2006","journal-title":"Pediatrics"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jinf.2014.07.012","article-title":"Neonatal candidiasis: diagnosis, prevention, and treatment.","volume":"69(suppl 1)","author":"Greenberg","year":"2014","journal-title":"J Infect"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1128\/AAC.01172-16","article-title":"High-dose micafungin for preterm neonates and infants with invasive and central nervous system Candidiasis.","volume":"60","author":"Auriti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants.","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clp.2010.01.016","article-title":"The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system\u2013tools for \u201cmeaningful use\u201d in continuous quality improvement.","volume":"37","author":"Spitzer","year":"2010","journal-title":"Clin Perinatol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/MPH.0000000000000343","article-title":"Safety and effectiveness of Micafungin in Japanese pediatric patients: results of a postmarketing surveillance study.","volume":"37","author":"Kobayashi","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/INF.0000000000001268","article-title":"Pharmacokinetics and safety of Micafungin in infants supported with extracorporeal membrane oxygenation.","volume":"35","author":"Autmizguine","year":"2016","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201902000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:39:43Z","timestamp":1694558383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201902000-00006"}},"subtitle":["Application of an Established Pharmacokinetics Model to Electronic Health Records"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002045","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}